Rositsa Koleva-Kolarova
Rositsa Koleva-Kolarova
Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford
Verified email at - Homepage
Cited by
Cited by
Copper in the human organism
M Angelova, S Asenova, V Nedkova, R Koleva-Kolarova
Trakia journal of sciences 9 (1), 88-98, 2011
The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients
RG Koleva-Kolarova, MJW Greuter, M Van Kruchten, KM Vermeulen, ...
British Journal of Cancer 112 (10), 1617-1625, 2015
Simulation models in population breast cancer screening: a systematic review
RG Koleva-Kolarova, Z Zhan, MJW Greuter, TL Feenstra, GH De Bock
The Breast 24 (4), 354-363, 2015
Guidance for the harmonisation and improvement of economic evaluations of personalised medicine
H Vellekoop, S Huygens, M Versteegh, L Szilberhorn, T Zelei, B Nagy, ...
Pharmacoeconomics 39 (7), 771-788, 2021
Large expert-curated database for benchmarking document similarity detection in biomedical literature search
P Brown, Y Zhou
Database 2019, baz085, 2019
Financing and reimbursement models for personalised medicine: a systematic review to identify current models and future options
R Koleva-Kolarova, J Buchanan, H Vellekoop, S Huygens, M Versteegh, ...
Applied Health Economics and Health Policy 20 (4), 501-524, 2022
Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis
RG Koleva-Kolarova, MP Oktora, AL Robijn, MJW Greuter, AKL Reyners, ...
Cancer Treatment Reviews 55, 16-25, 2017
The net benefit of personalized medicine: a systematic literature review and regression analysis
H Vellekoop, M Versteegh, S Huygens, IC Ramos, L Szilberhorn, T Zelei, ...
Value in Health 25 (8), 1428-1438, 2022
A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening
RG Koleva-Kolarova, AM Daszczuk, C de Jonge, MKA Hantash, ZZ Zhan, ...
Maturitas 109, 81-88, 2018
Cost-effectiveness analysis of treating patients with NTRK-positive cancer with the histology-independent therapy entrectinib
S Huygens, H Vellekoop, M Versteegh, I Santi, L Szilberhorn, T Zelei, ...
Value in Health 26 (2), 193-203, 2023
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19· 67 million people and evaluation of model …
W Liao, CAC Coupland, J Burchardt, DR Baldwin, F Gleeson, D Baldwin, ...
The Lancet Respiratory Medicine 11 (8), 685-697, 2023
Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients
A Tsiachristas, G Vallance, R Koleva-Kolarova, H Taylor, L Solomons, ...
BMC cancer 22 (1), 458, 2022
To screen or not to screen for breast cancer? How do modelling studies answer the question?
RG Koleva-Kolarova, Z Zhan, MJW Greuter, TL Feenstra, GH De Bock
Current Oncology 22 (5), 380-382, 2015
Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK
R Koleva-Kolarova, H Vellekoop, S Huygens, M Versteegh, MR Mölken, ...
Personalized Medicine 20 (4), 339-355, 2023
Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations
KK Lim, R Koleva-Kolarova, P Chowienczyk, CDA Wolfe, J Fox-Rushby
The Pharmacogenomics Journal 21 (6), 625-637, 2021
Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems
R Koleva-Kolarova, H Vellekoop, S Huygens, M Versteegh, MR Mölken, ...
Personalized Medicine 20 (4), 357-374, 2023
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation
R Koleva-Kolarova, L Szilberhorn, T Zelei, H Vellekoop, B Nagy, ...
Personalized Medicine 20 (4), 305-319, 2023
A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations
KK Lim, R Koleva-Kolarova, J Fox-Rushby
PharmacoEconomics 40 (10), 989-1003, 2022
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies
B Nagy, T Zelei, H Vellekoop, S Huygens, M Versteegh, MR Mölken, ...
Personalized Medicine 20 (4), 401-411, 2023
Cost–effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young
G Kovács, D Nagy, L Szilberhorn, T Zelei, Z Gaál, H Vellekoop, ...
Personalized Medicine 20 (4), 375-385, 2023
The system can't perform the operation now. Try again later.
Articles 1–20